Guardant Health Showcases Colorectal Cancer Screening Innovations at ACG 2024 Meeting

Guardant Health Highlights Colorectal Cancer Screening Innovations at ACG 2024

Guardant Health, Inc., a leading precision oncology company based in Palo Alto, California, is set to present crucial findings at the upcoming American College of Gastroenterology (ACG) 2024 Annual Meeting in Philadelphia. Scheduled for October 25-30, the presentations will focus on the effectiveness of blood-based testing in increasing adherence to colorectal cancer (CRC) screening. With an analysis of over 350,000 patients revealing that less than 50% completed the recommended repeat stool-based screenings within four years, Guardant emphasizes the pressing need for alternative testing methods that can better engage patients in their screening processes.

Dr. Craig Eagle, Chief Medical Officer at Guardant Health, stresses that the current compliance issues underscore a critical gap in CRC screening. Early detection is essential for effective treatment, and the reliance on traditional stool-based tests has proven insufficient in driving patient follow-through. The presentations will delve into the one-year outcomes of the ECLIPSE study, which explored the implications of "false positive" results from the company’s Shield™ blood test for CRC. Notably, findings indicated no significant difference in the rates of non-colorectal malignancies between patients who tested positive and those who tested negative, further validating the potential of blood tests in enhancing screening practices.

The ACG meeting will showcase two pivotal presentations by Guardant Health. One will address the risk of non-colorectal cancers in patients who receive false positive results, while the other will present real-world adherence statistics related to stool-based testing, which has already garnered the ACG Presidential Poster Award. These discussions aim to shed light on the importance of adopting innovative screening methods that not only detect CRC early but also encourage consistent participation among patients.

In addition to highlighting their research, Guardant Health continues to engage with the oncology community through platforms like LinkedIn, X (formerly Twitter), and Facebook. Founded in 2012, the company is dedicated to revolutionizing cancer care with its advanced blood and tissue tests, real-world data analytics, and artificial intelligence, ultimately striving to enhance patient outcomes and extend cancer-free survival periods. As awareness around CRC screening improves, Guardant's commitment to innovation positions it as a key player in the evolving landscape of cancer diagnostics.